Lisa M. Kopp

1.4k total citations · 1 hit paper
30 papers, 993 citations indexed

About

Lisa M. Kopp is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lisa M. Kopp has authored 30 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pediatrics, Perinatology and Child Health and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lisa M. Kopp's work include Childhood Cancer Survivors' Quality of Life (11 papers), Sarcoma Diagnosis and Treatment (7 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). Lisa M. Kopp is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (11 papers), Sarcoma Diagnosis and Treatment (7 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). Lisa M. Kopp collaborates with scholars based in United States, Canada and China. Lisa M. Kopp's co-authors include Cecele J. Denman, Srinivas S. Somanchi, Dean A. Lee, Sourindra N. Maiti, Prasad V. Phatarpekar, Harjeet Singh, Laurence J.N. Cooper, M. Helen Huls, Lenka V. Hurton and V. V. Senyukov and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Lisa M. Kopp

29 papers receiving 981 citations

Hit Papers

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Prolifera... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
    2012 489 citations Cecele J. Denman, V. V. Senyukov et al. PLoS ONE profile →

Peers

Lisa M. Kopp
Yiming Luo United States
Chuanbo Zang United States
Janina Kamińska Poland
C. C. Zielinski Austria
Allison Rosenthal United States
Yaşar Yıldız Türkiye
Jochen Heymanns Germany
Michael J. Dugan United States
Derek Tang United States
Luís Meza United States
Yiming Luo United States
Lisa M. Kopp
Citations per year, relative to Lisa M. Kopp Lisa M. Kopp (= 1×) peers Yiming Luo

Countries citing papers authored by Lisa M. Kopp

Since Specialization
Citations

This map shows the geographic impact of Lisa M. Kopp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa M. Kopp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa M. Kopp more than expected).

Fields of papers citing papers by Lisa M. Kopp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa M. Kopp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa M. Kopp. The network helps show where Lisa M. Kopp may publish in the future.

Co-authorship network of co-authors of Lisa M. Kopp

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa M. Kopp. A scholar is included among the top collaborators of Lisa M. Kopp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa M. Kopp. Lisa M. Kopp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Vieito, María, Bert H. O’Neil, Ana Arance, et al.. (2024). 614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification. Annals of Oncology. 35. S492–S492. 2 indexed citations
3.
Chow, Eric J., Sanjeev Aggarwal, David R. Doody, et al.. (2023). Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. Journal of Clinical Oncology. 41(12). 2248–2257. 40 indexed citations
4.
Weiss, Aaron R., Safia K. Ahmed, Wendy Allen‐Rhoades, et al.. (2023). Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. Journal of Adolescent and Young Adult Oncology. 12(5). 792–793. 1 indexed citations
5.
Chow, Eric J., Richard Aplenc, Lynda M. Vrooman, et al.. (2021). Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 128(4). 788–796. 38 indexed citations
6.
Jacobs, Elizabeth T., et al.. (2021). Relationship Between Individual Health Beliefs and Fruit and Vegetable Intake and Physical Activity Among Cancer Survivors: Results from the Health Information National Trends Survey. Journal of Adolescent and Young Adult Oncology. 11(3). 259–267. 11 indexed citations
7.
Avutu, Viswatej, Aaron R. Weiss, Damon R. Reed, et al.. (2021). Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. Journal of Adolescent and Young Adult Oncology. 11(3). 328–332. 6 indexed citations
8.
Krailo, Mark, Allen Buxton, Pooja Hingorani, et al.. (2021). Outcome of patients with recurrent/refractory osteosarcoma enrolled in three recent phase II trials: A report from the Children’s Oncology Group.. Journal of Clinical Oncology. 39(15_suppl). 11530–11530. 4 indexed citations
9.
Howe, Carol, et al.. (2020). Dietary Interventions for Adult Survivors of Adolescent and Young Adult Cancers: A Systematic Review and Narrative Synthesis. Journal of Adolescent and Young Adult Oncology. 9(3). 315–327. 13 indexed citations
10.
11.
Kopp, Lisa M., Richard B. Womer, Cindy L. Schwartz, et al.. (2019). Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group. Cardio-Oncology. 5(1). 15–15. 28 indexed citations
12.
13.
Kopp, Lisa M., et al.. (2015). Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant. Journal of Adolescent and Young Adult Oncology. 4(1). 50–53. 5 indexed citations
14.
Kopp, Lisa M. & Emmanuel Katsanis. (2015). Targeted immunotherapy for pediatric solid tumors. OncoImmunology. 5(3). e1087637–e1087637. 9 indexed citations
15.
Kopp, Lisa M., et al.. (2014). Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma. Pediatric Blood & Cancer. 62(1). 12–15. 20 indexed citations
16.
Kopp, Lisa M., et al.. (2013). Small Cell Carcinoma of the Ovary of the Hypercalcemic Type Presenting in a 5-Year-Old Girl. Journal of Pediatric Hematology/Oncology. 35(5). e217–e218. 2 indexed citations
17.
Kopp, Lisa M., et al.. (2012). Late Effects in Adult Survivors of Pediatric Cancer: A Guide for the Primary Care Physician. The American Journal of Medicine. 125(7). 636–641. 32 indexed citations
18.
Denman, Cecele J., V. V. Senyukov, Srinivas S. Somanchi, et al.. (2012). Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PLoS ONE. 7(1). e30264–e30264. 489 indexed citations breakdown →
19.
Anderson, Pete, Lisa M. Kopp, Nicholas R. Anderson, et al.. (2008). Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opinion on Investigational Drugs. 17(11). 1703–1715. 60 indexed citations
20.
Kopp, Lisa M., et al.. (2008). All‐trans‐retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatric Blood & Cancer. 51(1). 133–135. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yiming Luo Breakdown of academic impact, for papers by Chuanbo Zang Breakdown of academic impact, for papers by Janina Kamińska Breakdown of academic impact, for papers by C. C. Zielinski Breakdown of academic impact, for papers by Allison Rosenthal Breakdown of academic impact, for papers by Yaşar Yıldız Breakdown of academic impact, for papers by Jochen Heymanns Breakdown of academic impact, for papers by Michael J. Dugan Breakdown of academic impact, for papers by Derek Tang Breakdown of academic impact, for papers by Luís Meza
Rankless by CCL
2026